Genzyme, Cobrek End Kidney Drug Patent Fight

Law360, New York (December 14, 2012, 5:25 PM EST) -- Genzyme Corp. and Cobrek Pharmaceuticals Inc. on Thursday agreed to end a suit in Illinois federal court in which Genzyme accused Cobrek of infringing a patent covering kidney disease treatment Hectorol with a generic version of a renal drug.

Genzyme will dismiss its claims against Cobrek without prejudice, while Cobrek will dismiss its counterclaims against Genzyme with prejudice, according to a joint stipulation of dismissal filed in the Northern District of Illinois.

The parties couldn't immediately be reached for comment Friday.

The dispute dates back to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.